Immunotherapy 'Shock' with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma
| Autor: | Aggeliki Rapti, Dimitrios Drougas, Chong Bai, Chrysa Sardeli, Haidong Huang, Liana Papaemmanouil, Christoforos Kosmidis, Dimitrios Hatzibougias, Paul Zarogoulidis, Wolfgang Hohenforst-Schmidt, Lemonia Veletza, Georgia Trakada, Anastasios Kallianos, Theodora Tsiouda |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty medicine.medical_treatment Case Report Vitiligo Adenocarcinoma NSCLC 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Adverse effect lcsh:RC705-779 Lung business.industry lcsh:Diseases of the respiratory system Immunotherapy medicine.disease Nivolumab 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Shock (circulatory) EBUS medicine.symptom business Tyrosine kinase |
| Zdroj: | Respiratory Medicine Case Reports Respiratory Medicine Case Reports, Vol 22, Iss C, Pp 283-286 (2017) |
| ISSN: | 2213-0071 |
| Popis: | Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified. We report a rare case of a patient with lung cancer adenocarcinoma who developed vitiligo throughout his body after nivolumab administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|